Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US00287Y1091
Ticker ABBV
Company ABBVIE
Currency $
Price
Aware Investor Index (AII) 647.9931
Recommendation STRONG BUY
P/E 25.39
ROE 100.00 %
Capitalization 115,563,500,000 $
Dividend Yield 5.28 %
P/S 3.53
AII Position 10
P/E Position 369
ROE Position 21
Capitalization Position 77
Dividend Yield Position 92
Sales 32,753,000,000 $
10-Year Average Earnings 4,551,700,000 $
Shares Outstanding 1,546,000,000
Equity -8,446,000,000 $
Dividend per Share 3.95 $
Industry Pharmaceutical
Country United States
ABBVIE Investor Relations Web Site http://www.abbvieinvestor.com







Sales:

YEAR MONTH AMOUNT
2018 12 32,753,000,000.00 $
2017 12 28,216,000,000.00 $
2016 12 25,638,000,000.00 $
2015 12 22,859,000,000.00 $
2014 12 19,960,000,000.00 $
2013 12 18,790,000,000.00 $
2012 12 18,380,000,000.00 $
2011 12 17,444,000,000.00 $
2010 12 15,638,000,000.00 $
2009 12 14,214,000,000.00 $

Earnings:

YEAR MONTH AMOUNT
2018 12 5,687,000,000.00 $
2017 12 5,309,000,000.00 $
2016 12 5,953,000,000.00 $
2015 12 5,144,000,000.00 $
2014 12 1,774,000,000.00 $
2013 12 4,128,000,000.00 $
2012 12 5,275,000,000.00 $
2011 12 3,433,000,000.00 $
2010 12 4,178,000,000.00 $
2009 12 4,636,000,000.00 $

Equity:

YEAR MONTH AMOUNT
2018 12 -8,446,000,000.00 $
2017 12 5,097,000,000.00 $
2016 12 4,636,000,000.00 $
2015 12 3,945,000,000.00 $
2014 12 1,742,000,000.00 $
2013 12 4,492,000,000.00 $
2012 12 3,363,000,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2018 12 1,546,000,000
2017 12 1,603,000,000
2016 12 1,631,000,000
2015 12 1,637,000,000
2014 12 1,610,000,000
2013 12 1,604,000,000
2012 12 1,577,000,000

 












Bloomberg News for ABBVIE:



Google News for ABBVIE:

TheStreet.com - 3 days ago
The Long Decline in AbbVie Is Over
That's why Cramer recommended AbbVie (ABBV) , which will soon close on its acquisition of Allergan (AGN) . Cramer said Wall Street is only ...
Yahoo Finance - 4 days ago
Is AbbVie (ABBV) Stock Undervalued Right Now?
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our ...
Yahoo Finance - 6 days ago
AbbVie (ABBV) Gains As Market Dips: What You Should Know
AbbVie (ABBV) closed the most recent trading day at $73.76, moving +0.18% from the previous trading session. The stock outpaced the S&P ...
Yahoo Finance - 6 days ago
This is Why AbbVie (ABBV) is a Great Dividend Stock
AbbVie (ABBV) is headquartered in North Chicago, and is in the Medical sector. The stock has seen a price change of -20.13% since the start ...
StreetInsider.com - 2 days ago
AbbVie (ABBV) Receives CHMP Positive Opinion for Upadacitinib ...
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Medicines Agency's (EMA) ...
The Dwinnex - 2 days ago
AbbVie Inc. [ABBV] – Don't lose sight of the bigger picture
AbbVie Inc. [NYSE: ABBV] stock went up by 2.42% or 1.82 points up from its previous closing price of $75.14. The stock reached $76.96 during ...
MЕSА Wееkly
AbbVie (ABBV) Stock Moves -0.44%: What You Should Know
In the latest trading session, AbbVie (ABBV) closed at $74.33, marking a -0.44% move from the previous day. This change was narrower than ...
US Post News
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
AbbVie (ABBV) closed the most recent trading day at $75.73, moving +1.18% from the previous trading session. This change outpaced the S&P ...
Riverton Roll
AbbVie Inc. [ABBV] – The Fundamentals are a good enough reason ...
AbbVie Inc.[ABBV] stock saw a move by 0.72% on Thursday, touching 3.42 million. Based on the recent volume, AbbVie Inc. stock traders ...
Yahoo Finance - 7 Oct 2019
AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug
AbbVie Inc. ABBV announced that the FDA approved the label expansion of Mavyret (glecaprevir/pibrentasvir). The agency approved the drug ...


Back